The First Kilogram Synthesis of Beclabuvir, an HCV NS5B Polymerase Inhibitor-Reference-Cited by-同舟云学术

The First Kilogram Synthesis of Beclabuvir, an HCV NS5B Polymerase Inhibitor

Published:2018-08-16 Issue:10 Volume:22 Page:1393-1408
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Bien Jeffrey¹,Davulcu Akin¹,DelMonte Albert J.¹^ORCID,Fraunhoffer Kenneth J.¹,Gao Zhinong¹,Hang Chao¹,Hsiao Yi¹,Hu Wenhao¹,Katipally Kishta¹,Littke Adam¹,Pedro Aghogho¹,Qiu Yuping¹,Sandoval Maria¹,Schild Richard¹,Soltani Michelle¹,Tedesco Anthony¹,Vanyo Dale¹,Vemishetti Purushotham¹,Waltermire Robert E.¹

Affiliation:

1. Chemical and Synthetic Development, Bristol-Myers Squibb Company, One Squibb Drive, P.O. Box 191, New Brunswick, New Jersey 08903, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.8b00214

Reference18 articles.

1. Global distribution and prevalence of hepatitis C virus genotypes

2. Recent advances on the synthesis of hepatitis C virus NS5B RNA-dependent RNA-polymerase inhibitors

3. Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase